ADPT Adaptive Biotechnologies Corp

USD 3.13 -0.17 -5.151515
Icon

Adaptive Biotechnologies Corp (ADPT) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 3.13

-0.17 (-5.15)%

USD 0.48B

0.69M

USD 5.00(+59.74%)

USD 8.33 (+166.13%)

Icon

ADPT

Adaptive Biotechnologies Corp (USD)
COMMON STOCK | NSD
USD 3.13
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

Strong Buy

Average User
Rating

USD 0.48B

USD 8.33 (+166.13%)

USD 3.13

Adaptive Biotechnologies Corp (ADPT) Stock Forecast

Show ratings and price targets of :
USD 5.00
(+59.74%)

Based on the Adaptive Biotechnologies Corp stock forecast from 3 analysts, the average analyst target price for Adaptive Biotechnologies Corp is USD 5.00 over the next 12 months. Adaptive Biotechnologies Corp’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Adaptive Biotechnologies Corp is Bearish, which is based on 1 positive signals and 5 negative signals. At the last closing, Adaptive Biotechnologies Corp’s stock price was USD 3.13. Adaptive Biotechnologies Corp’s stock price has changed by -13.30% over the past week, -20.96% over the past month and -63.22% over the last year.

No recent analyst target price found for Adaptive Biotechnologies Corp
No recent average analyst rating found for Adaptive Biotechnologies Corp

Company Overview Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and mac...Read More

1165 Eastlake Avenue East, Seattle, WA, United States, 98109

709

December

USD

USA

Adjusted Closing Price for Adaptive Biotechnologies Corp (ADPT)

Loading...

Unadjusted Closing Price for Adaptive Biotechnologies Corp (ADPT)

Loading...

Share Trading Volume for Adaptive Biotechnologies Corp Shares

Loading...

Compare Performance of Adaptive Biotechnologies Corp Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ADPT

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Adaptive Biotechnologies Corp (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX
Vertex Pharmaceuticals Inc +1.70 (+0.35%) USD124.65B 31.35 20.00

ETFs Containing ADPT

Symbol Name ADPT's Weight Expense Ratio Price(Change) Market Cap
no data

Frequently Asked Questions About Adaptive Biotechnologies Corp (ADPT) Stock

Based on ratings from 3 analysts Adaptive Biotechnologies Corp's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 2 buy, sell and 1 hold ratings.

Unfortunately we do not have enough data on ADPT's stock to indicate if its a good dividend stock.

Based on targets from 3 analysts, the average taret price for ADPT is USD 5.00 over the next 12 months. The maximum analyst target price is USD 5 while the minimum anlayst target price is USD 5.

ADPT stock's Price/Earning ratio is 43.96. Our analysis grades ADPT stock's Price / Earning ratio at F. This means that ADPT stock's Price/Earning ratio is above 83% of the stocks in the Biotechnology sector in the NSD exchange. Based on this ADPT may be a overvalued for its sector.

The last closing price of ADPT's stock was USD 3.13.

The most recent market capitalization for ADPT is USD 0.48B.

Based on targets from 3 analysts, the average taret price for ADPT is projected at USD 5.00 over the next 12 months. This means that ADPT's stock price may go up by +59.74% over the next 12 months.

We can't find any ETFs which contains Adaptive Biotechnologies Corp's stock.

As per our most recent records Adaptive Biotechnologies Corp has 709 Employees.

Adaptive Biotechnologies Corp's registered address is 1165 Eastlake Avenue East, Seattle, WA, United States, 98109. You can get more information about it from Adaptive Biotechnologies Corp's website at https://www.adaptivebiotech.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...